AAPL351.91-0.87 (-0.25%) ▼|ABBV292.82-1.73 (-0.59%) ▼|ABT104.71-2.74 (-2.55%) ▼|ACN239.28-8.42 (-3.40%) ▼|ADBE235.55-10.45 (-4.25%) ▼|AMAT349.23-1.02 (-0.29%) ▼|AMD503.41-0.87 (-0.17%) ▼|AMGN457.93-4.39 (-0.95%) ▼|AMT183.18-7.56 (-3.96%) ▼|AMZN257.89+0.14 (+0.05%) ▲|AVGO341.60+8.20 (+2.46%) ▲|AXP315.78-3.27 (-1.02%) ▼|BA163.91-1.31 (-0.79%) ▼|BAC49.44-0.64 (-1.28%) ▼|BKNG154.46-3.07 (-1.95%) ▼|BLK1,180.67-17.30 (-1.44%) ▼|BMY61.35-1.58 (-2.51%) ▼|BNY149.79-1.90 (-1.25%) ▼|BRK-B586.76-6.09 (-1.03%) ▼|C119.94-1.38 (-1.14%) ▼|CAT570.79+0.30 (+0.05%) ▲|CL99.61-1.38 (-1.37%) ▼|CMCSA25.31-0.29 (-1.13%) ▼|COF186.78-6.44 (-3.33%) ▼|COP139.48-1.04 (-0.74%) ▼|COST1,110.08-3.66 (-0.33%) ▼|CRM194.52-20.31 (-9.45%) ▼|CSCO95.11+0.59 (+0.62%) ▲|CVS85.81-2.78 (-3.14%) ▼|CVX216.13-1.01 (-0.47%) ▼|DE649.23-4.76 (-0.73%) ▼|DHR225.77-4.14 (-1.80%) ▼|DIS116.94-1.76 (-1.48%) ▼|DUK129.84-0.75 (-0.57%) ▼|EMR159.15-1.50 (-0.93%) ▼|FDX319.94-7.71 (-2.35%) ▼|GD355.63-4.06 (-1.13%) ▼|GE326.40+1.22 (+0.38%) ▲|GEV779.91+16.34 (+2.14%) ▲|GILD170.26+2.68 (+1.60%) ▲|GM84.05+0.38 (+0.45%) ▲|GOOG277.60-3.66 (-1.30%) ▼|GOOGL280.20-3.52 (-1.24%) ▼|GS877.52-14.02 (-1.57%) ▼|HD339.01-8.50 (-2.45%) ▼|HON218.96+1.01 (+0.46%) ▲|IBM231.09-11.42 (-4.71%) ▼|INTC55.17-0.27 (-0.49%) ▼|INTU320.79-24.77 (-7.17%) ▼|ISRG430.53-7.22 (-1.65%) ▼|JNJ278.70-3.85 (-1.36%) ▼|JPM329.96-8.25 (-2.44%) ▼|KO98.79-0.69 (-0.69%) ▼|LIN515.11-8.35 (-1.60%) ▼|LLY1,415.55-16.12 (-1.13%) ▼|LMT590.34+5.13 (+0.88%) ▲|LOW220.46-4.47 (-1.99%) ▼|LRCX210.69-0.14 (-0.07%) ▼|MA645.73-15.98 (-2.42%) ▼|MCD275.82+1.15 (+0.42%) ▲|MDLZ66.75-0.79 (-1.17%) ▼|MDT102.32-0.56 (-0.54%) ▼|META618.87-7.54 (-1.20%) ▼|MMM180.88-0.80 (-0.44%) ▼|MO77.46-1.44 (-1.83%) ▼|MRK143.37-1.09 (-0.75%) ▼|MS183.53-2.04 (-1.10%) ▼|MSFT506.24-11.75 (-2.27%) ▼|MU712.42-6.60 (-0.92%) ▼|NEE84.42-0.92 (-1.08%) ▼|NFLX59.68-1.07 (-1.76%) ▼|NKE35.85-2.41 (-6.30%) ▼|NOW92.90-6.47 (-6.51%) ▼|NVDA155.46-0.68 (-0.44%) ▼|ORCL115.00-4.09 (-3.43%) ▼|PEP142.02-4.41 (-3.01%) ▼|PFE28.47-0.39 (-1.35%) ▼|PG171.72-1.30 (-0.75%) ▼|PLTR156.56-3.83 (-2.39%) ▼|PM194.38-1.66 (-0.85%) ▼|QCOM166.67-1.85 (-1.10%) ▼|RTX198.00+3.11 (+1.60%) ▲|SBUX107.49-1.23 (-1.13%) ▼|SCHW91.84-1.10 (-1.18%) ▼|SO93.60-1.04 (-1.10%) ▼|SPG230.24-2.54 (-1.09%) ▼|T22.29-0.07 (-0.31%) ▼|TMO686.79-4.54 (-0.66%) ▼|TMUS167.90-2.11 (-1.24%) ▼|TSLA380.11+0.37 (+0.10%) ▲|TXN295.86+1.65 (+0.56%) ▲|UBER68.81-1.18 (-1.69%) ▼|UNH389.68-22.34 (-5.42%) ▼|UNP297.03-6.68 (-2.20%) ▼|UPS110.31-1.51 (-1.35%) ▼|USB59.18-1.25 (-2.07%) ▼|V416.77-9.69 (-2.27%) ▼|VZ45.93-0.41 (-0.88%) ▼|WFC82.69-2.15 (-2.53%) ▼|WMT127.52-0.89 (-0.69%) ▼|XOM167.21+0.34 (+0.20%) ▲|AAPL351.91-0.87 (-0.25%) ▼|ABBV292.82-1.73 (-0.59%) ▼|ABT104.71-2.74 (-2.55%) ▼|ACN239.28-8.42 (-3.40%) ▼|ADBE235.55-10.45 (-4.25%) ▼|AMAT349.23-1.02 (-0.29%) ▼|AMD503.41-0.87 (-0.17%) ▼|AMGN457.93-4.39 (-0.95%) ▼|AMT183.18-7.56 (-3.96%) ▼|AMZN257.89+0.14 (+0.05%) ▲|AVGO341.60+8.20 (+2.46%) ▲|AXP315.78-3.27 (-1.02%) ▼|BA163.91-1.31 (-0.79%) ▼|BAC49.44-0.64 (-1.28%) ▼|BKNG154.46-3.07 (-1.95%) ▼|BLK1,180.67-17.30 (-1.44%) ▼|BMY61.35-1.58 (-2.51%) ▼|BNY149.79-1.90 (-1.25%) ▼|BRK-B586.76-6.09 (-1.03%) ▼|C119.94-1.38 (-1.14%) ▼|CAT570.79+0.30 (+0.05%) ▲|CL99.61-1.38 (-1.37%) ▼|CMCSA25.31-0.29 (-1.13%) ▼|COF186.78-6.44 (-3.33%) ▼|COP139.48-1.04 (-0.74%) ▼|COST1,110.08-3.66 (-0.33%) ▼|CRM194.52-20.31 (-9.45%) ▼|CSCO95.11+0.59 (+0.62%) ▲|CVS85.81-2.78 (-3.14%) ▼|CVX216.13-1.01 (-0.47%) ▼|DE649.23-4.76 (-0.73%) ▼|DHR225.77-4.14 (-1.80%) ▼|DIS116.94-1.76 (-1.48%) ▼|DUK129.84-0.75 (-0.57%) ▼|EMR159.15-1.50 (-0.93%) ▼|FDX319.94-7.71 (-2.35%) ▼|GD355.63-4.06 (-1.13%) ▼|GE326.40+1.22 (+0.38%) ▲|GEV779.91+16.34 (+2.14%) ▲|GILD170.26+2.68 (+1.60%) ▲|GM84.05+0.38 (+0.45%) ▲|GOOG277.60-3.66 (-1.30%) ▼|GOOGL280.20-3.52 (-1.24%) ▼|GS877.52-14.02 (-1.57%) ▼|HD339.01-8.50 (-2.45%) ▼|HON218.96+1.01 (+0.46%) ▲|IBM231.09-11.42 (-4.71%) ▼|INTC55.17-0.27 (-0.49%) ▼|INTU320.79-24.77 (-7.17%) ▼|ISRG430.53-7.22 (-1.65%) ▼|JNJ278.70-3.85 (-1.36%) ▼|JPM329.96-8.25 (-2.44%) ▼|KO98.79-0.69 (-0.69%) ▼|LIN515.11-8.35 (-1.60%) ▼|LLY1,415.55-16.12 (-1.13%) ▼|LMT590.34+5.13 (+0.88%) ▲|LOW220.46-4.47 (-1.99%) ▼|LRCX210.69-0.14 (-0.07%) ▼|MA645.73-15.98 (-2.42%) ▼|MCD275.82+1.15 (+0.42%) ▲|MDLZ66.75-0.79 (-1.17%) ▼|MDT102.32-0.56 (-0.54%) ▼|META618.87-7.54 (-1.20%) ▼|MMM180.88-0.80 (-0.44%) ▼|MO77.46-1.44 (-1.83%) ▼|MRK143.37-1.09 (-0.75%) ▼|MS183.53-2.04 (-1.10%) ▼|MSFT506.24-11.75 (-2.27%) ▼|MU712.42-6.60 (-0.92%) ▼|NEE84.42-0.92 (-1.08%) ▼|NFLX59.68-1.07 (-1.76%) ▼|NKE35.85-2.41 (-6.30%) ▼|NOW92.90-6.47 (-6.51%) ▼|NVDA155.46-0.68 (-0.44%) ▼|ORCL115.00-4.09 (-3.43%) ▼|PEP142.02-4.41 (-3.01%) ▼|PFE28.47-0.39 (-1.35%) ▼|PG171.72-1.30 (-0.75%) ▼|PLTR156.56-3.83 (-2.39%) ▼|PM194.38-1.66 (-0.85%) ▼|QCOM166.67-1.85 (-1.10%) ▼|RTX198.00+3.11 (+1.60%) ▲|SBUX107.49-1.23 (-1.13%) ▼|SCHW91.84-1.10 (-1.18%) ▼|SO93.60-1.04 (-1.10%) ▼|SPG230.24-2.54 (-1.09%) ▼|T22.29-0.07 (-0.31%) ▼|TMO686.79-4.54 (-0.66%) ▼|TMUS167.90-2.11 (-1.24%) ▼|TSLA380.11+0.37 (+0.10%) ▲|TXN295.86+1.65 (+0.56%) ▲|UBER68.81-1.18 (-1.69%) ▼|UNH389.68-22.34 (-5.42%) ▼|UNP297.03-6.68 (-2.20%) ▼|UPS110.31-1.51 (-1.35%) ▼|USB59.18-1.25 (-2.07%) ▼|V416.77-9.69 (-2.27%) ▼|VZ45.93-0.41 (-0.88%) ▼|WFC82.69-2.15 (-2.53%) ▼|WMT127.52-0.89 (-0.69%) ▼|XOM167.21+0.34 (+0.20%) ▲|
11.4 C
New York
Wednesday, November 18, 2026

Tag: FOR

ROHM Introduces New MOSFET for AI Servers with Industry-leading SOA Performance and Low ON-resistance

-Endorsed by Major Global Cloud Platform Provider- KYOTO, Japan, July 1, 2025 /PRNewswire/ -- ROHM has released the RY7P250BM, 100V power MOSFET optimized for hot-swap...

Potech Showcases Darkivore – the Cybersecurity Platform – at Edunet 2025

Real-World Cyberbullying Case at an Australian School, Highlights Urgent Need for External Threat Response in Schools MELBOURNE, Australia, July 1, 2025 /PRNewswire/ -- Potech, a global...

HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach

TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology...

ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits CE Mark Application

EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world.

From Gaza to Africa: Equalall widens its Urgent Global Fundraising Drive to Support Crisis-Affected Communities in Africa

Global non-profit Equalall has so far been involved in fundraising for and mobilizing life-saving aid for victims of war, displacement, and natural disasters in Gaza, Syria, Sudan
Global non-profit Equalall has so far been involved in fundraising for and mobilizing life-saving aid for victims of war, displacement, and natural disasters in Gaza, Syria, Sudan

Trip.com Group Pioneers a Greener, More Inclusive Global Travel Ecosystem in 2024 Sustainability Report

Group launches new full-scale carbon emissions data feature across transport modesCountry Retreats Programme expands to more global destinations, driving rural developmentChampioning greater inclusion in...

Sodexo Q3 Fiscal 2025 revenues in line with expectations

Issy-les-Moulineaux, July 1, 2025 (7am)
Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY)

ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility

LAUSANNE, Switzerland and COPENHAGEN, Denmark, July 01, 2025 (GLOBE NEWSWIRE) -- ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that the first participant has been included in the company’s Phase 2 clinical trial of its lead candidate RPN-001 (leflutrozole), an orally administered aromatase inhibitor in development for the treatment of male infertility (https://clinicaltrials.gov/study/NCT06993155?term=Leflutrozole&rank=1).

Apolonia Capital Secures Full Regulatory License from UAE Securities and Commodities Authority (SCA)

DUBAI, UAE, July 1, 2025 /PRNewswire/ -- Apolonia Capital, a UAE-headquartered firm, is proud to announce that it has received its full regulatory license...

Atlas Corp. and subsidiary Seaspan Corporation release 2024 Sustainability Report

LONDON, UK, July 1, 2025 /PRNewswire/ -- Atlas Corp. (Atlas) is proud to present its 2024 Sustainability Report, the fifth annual report on the...

IBSAT 2025, an MBA/PGPM Entrance Exam for 9 campuses of ICFAI Business School, opens July 1, 2025

HYDERABAD, India, July 1, 2025 /PRNewswire/ -- IBSAT is an online aptitude test conducted by The ICFAI Foundation for Higher Education (The IFHE), Hyderabad...

Commencement of Chief Executive Officer

PERTH, Australia, July 01, 2025 (GLOBE NEWSWIRE) -- Canyon Resources Limited (ASX: CAY) (‘Canyon’ or the ‘Company’) is pleased to announce that Mr Peter Secker has officially commenced his role as Chief Executive Officer (CEO), effective 1 July 2025.

Baidu Announces Management Changes

BEIJING, July 1, 2025 /PRNewswire/ -- Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu" or the "Company"), a leading...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFOR